RTD focus of organization
Description of RTD activities
Insulin, IGF-1, Ang II, Estradiol, Diabetes, Hypertension, Signal transduction, Diabetes, Cardiovascular biology, Metabolic syndrome
Experiences in international Programmes
2000-2003: Pilot Project Program, Deans Initiative inResearch Investment, Vascular Interaction of Estradioland IGF-1 in Insulin Resistance, Principal Invest.: EsmaIsenovic, Ph.D. 2000-2003: NIH (1 R01 HL66119-01) Ang II and IGF-1Interaction in Cardiovascular Tissue, Co-Investigator: 2001-2003: NOVARTIS: Effect of Inhibition of the ReninAngiotensin System (RAS) on Insulin Sensitivity inVascular Smooth Muscle Cells (VSMC) and EndothelialCells (EC): Valsartan Effects on Insulin Mediated NitricOxide Production, Sodium Pump Activation and GlucoseTransport, Co-Investigator: Esma Isenovic, Ph.D. 2003-2003: NIH (1 R01) Ang II Opposes Insulin MediatedVasorelaxation and Glucose Utilization: Role of ROS and RhoA, Co-Investigator: Esma Isenovic, Ph.D., 2002-2003: VA Merit Review Vascular Protein Kinase B/Akt and Rho Signaling, Co-Investigator: Esma Isenovic, Ph.D 2004-present EU coperation Grant COST B17: Obesityand Diabetes mellitus in the Elderly, Principal Invest.:Esma Isenovic, Ph.D. 2004-present European Commission Framework Programme: EqualProject (EC4): Multi-National External Quality Assay (EQA) Programmes in Clinical Molecular Diagnostics based on Performance and Interpretation of PCR assay including dissemination and training, supported by the European Community within the FP6 programme.Principal Invest.: Esma Isenovic, Ph.D. 2005: pending- Collaborative Grant with University of Ljubljana, School of Medicine, Response to insulin on cellular level Principal Invest.: Esma Isenovic, Ph.D.
Organisation is/was involved in projects funded by the following RTD programmes
Inserted / Updated
2005-11-01 / 2010-01-22